Search

everythinglearnresearchcommunity

for

Search:↓

A 25-year-old male experiencing hair loss and thinning since age 20 is seeking advice on effective DHT inhibitors. He lists various oral and topical treatments, excluding Minoxidil due to adverse effects.

A user has been treating hair loss with finasteride for two years without success and is experiencing an itchy scalp with seborrhea. Despite low DHT levels, they are still losing hair, suggesting that DHT might not be the main cause of their hair loss, and they are considering other treatments or causes.

The user is experiencing diffuse thinning and has tried treatments like topical and oral finasteride, oral dutasteride, topical minoxidil, microneedling, melatonin, and caffeine without success. Despite using these treatments for over four years, the user reports continued hair thinning and is considering trying RU58841.

Hair loss due to low Vitamin D levels improved significantly after taking 4000UI Vitamin D capsules and vitamin B supplements. The user noticed a reduction in hair shedding within a week.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

The user has been using Finasteride 1mg daily for 13 years with stable results but is now experiencing thinning hair and is considering switching to Dutasteride 0.5mg. They are seeking advice on whether this change might be beneficial.

Considering a hair transplant for diffuse thinning may harm existing follicles. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is experiencing hair regrowth after two months using topical finasteride, minoxidil spray, and weekly microneedling. They report less hair loss and stronger hair growth.

The conversation discusses hair loss treatments, specifically increasing the dose of dutasteride from 0.5 to 2.5 mg, and the resulting hair shedding. Users share mixed experiences, with some seeing improvement after shedding and others finding higher doses less effective.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.

The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The user is experiencing increased hair shedding after one year of using oral dutasteride. They are seeking opinions on their DHT test results, which show levels below baseline.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The user shared their 18-month hair loss treatment progress, using finasteride three times a week, daily minoxidil, weekly vitamin D, and bi-weekly nizoral shampoo. They experienced initial shedding and greying, but are satisfied with the results.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.

The conversation is about hair regrowth progress using oral dutasteride (DUT) and minoxidil (MIN) over three months, with significant improvement noted. Users discuss potential future results and share personal experiences with similar treatments.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

A user's experience with hair loss and their current regimen of RU58841, Dutasteride 0.5mg, Minoxidil 2.5mg, and Finasteride 1mg to attempt regrowth.